Cannabidiol
From Wikipedia, the free encyclopedia
Cannabidiol
|
|
Systematic (IUPAC) name | |
2-((1S,6S)-3-methyl-6-(prop-1-en-2-yl) cyclohex-2-enyl)-5-pentylbenzene-1,3-diol |
|
Identifiers | |
CAS number | 13956-29-1 |
ATC code | noentry |
PubChem | 644019 |
DrugBank | none |
Chemical data | |
Formula | C21H30O2 |
Mol. weight | 314.46 |
SMILES | CCCCCC(C=C1O)=CC(O)=C1[C@]2 (C=C(C)CC[C@]2([H])C(C)=C)[H] |
Physical data | |
Melt. point | 66 °C (151 °F) |
Pharmacokinetic data | |
Bioavailability | ? |
Metabolism | ? |
Half life | ? |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status | |
Routes | ? |
Cannabidiol, also known as CBD, is a non-psychoactive cannabinoid found in the hemp plant Cannabis sativa.
CBD alone is not psychoactive, but it appears to reduce the euphoric effect of THC (which is an isomer of cannabidiol) and add a sedative quality. It may decrease the rate of THC clearance from the body, perhaps by interfering with the metabolism of THC in the liver. Medically, it appears to relieve convulsion, inflammation, anxiety, and nausea. CBD has a greater affinity for the CB2 receptor than for the CB1 receptor. It is perceived to have more effect on the body.
[edit] Medicinal use
In April 2005, Canadian authorities approved the marketing of Sativex, a mouth spray for multiple sclerosis to alleviate pain. Sativex contains tetrahydrocannabinol together with cannabidiol. It is marketed in Canada by GW Pharmaceuticals.
[edit] See also
- Cannabinoids
- Cannabinoid receptors
- Cannabis
- Health issues and the effects of cannabis
- Medical marijuana
[edit] External links
- Erowid Compounds found in Cannabis sativa